What Changed at Myriad Genetics

Every material change AI Health Index has tracked at Myriad Genetics: new modules, model and architecture updates, clinical evidence, regulatory status, security certifications, and integration depth. Each entry states what changed, cites its source, and carries our read on what it means for a buyer. The graded assessment of this vendor across all fifteen capability axes sits on its index profile.

Funding rounds, valuations, and awards are not product changes and are not logged here. Acquisitions appear only where there is direct product impact.

Follow this change log by RSS

Free for your reader, newsletter or automation tool. One feed covers the whole index, and every category has its own.

All feeds and terms

Impact

Type

1 entry

Showing changes for Myriad Genetics only.Show the full log

October 2026

M

Myriad Genetics

Oct 22, 2026

MediumVerified

Clinical evidence

Myriad released MONSTAR-SCREEN-3 data on Precise MRD, its whole genome sequencing test for residual cancer, presented at ESMO 2026. In resectable colorectal cancer the test found tumor DNA before clinical recurrence in every recurrence observed, with a median lead time of four months, and more than half of positive results after surgery were below 100 parts per million. In resectable pancreatic cancer, a positive result one month after surgery was linked to significantly worse recurrence free survival.

Our read

Many positives sat at very low levels, which is where a whole genome approach is meant to beat smaller panels. Lead time is not yet evidence that acting earlier changes outcomes, which is the data oncologists will want next.

Related axis: Clinical and Operational EvidenceVendor announcementView source

What has changed at Myriad Genetics recently?

The most recent change AI Health Index logged at Myriad Genetics is dated Oct 22, 2026. Myriad released MONSTAR-SCREEN-3 data on Precise MRD, its whole genome sequencing test for residual cancer, presented at ESMO 2026.